{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:09:45Z","timestamp":1791356985376,"version":"4.3.1"},"reference-count":197,"publisher":"Elsevier BV","issue":"19","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,16]],"date-time":"2027-06-16T00:00:00Z","timestamp":1813104000000},"content-version":"am","delay-in-days":258,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015691","name":"National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI170546"],"award-info":[{"award-number":["R01 AI170546"]}],"id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01 GM126363"],"award-info":[{"award-number":["R01 GM126363"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R35GM128696"],"award-info":[{"award-number":["R35GM128696"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular Biology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jmb.2026.169892","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:08:03Z","timestamp":1780474083000},"page":"169892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War"],"prefix":"10.1016","volume":"438","author":[{"given":"Chelsea A.","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Dewar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2550-4884","authenticated-orcid":false,"given":"Neil","family":"Osheroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmb.2026.169892_b0005","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3201\/eid2305.161556","article-title":"The discovery of penicillin-new insights after more than 75 years of clinical use","volume":"5","author":"Gaynes","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.mib.2019.10.008","article-title":"Antibiotics: past, present and future","volume":"51","author":"Hutchings","year":"2019","journal-title":"Curr. Opin. Microbiol."},{"key":"10.1016\/j.jmb.2026.169892_b0015","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/cid\/ciz225","article-title":"Changes in US outpatient antibiotic prescriptions from 2011\u20132016","volume":"70","author":"King","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0020","series-title":"Outpatient Antibiotic Prescriptions\u2014United States, 2017","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"10.1016\/j.jmb.2026.169892_b0025","unstructured":"Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report Achievements in Public Health, 1900\u20131999 Control of Infectious Diseases, 29 ed., 1999, pp. 621\u2013626."},{"key":"10.1016\/j.jmb.2026.169892_b0030","unstructured":"Centers for Disease Control and Prevention, About Antimicrobial Resistance, 2025."},{"key":"10.1016\/j.jmb.2026.169892_b0035","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.jiph.2021.10.020","article-title":"Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects","volume":"14","author":"Uddin","year":"2021","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/j.jmb.2026.169892_b0040","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jmb.2026.169892_b0045","unstructured":"World Health Organization, Antimicrobial Resistance, 2023."},{"key":"10.1016\/j.jmb.2026.169892_b0050","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/jac\/dkv484","article-title":"Antibiotics: from prehistory to the present day","volume":"71","author":"Gould","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0055","doi-asserted-by":"crossref","DOI":"10.1057\/s41599-019-0251-8","article-title":"Antimicrobials before antibiotics: war, peace, and disinfectants","volume":"5","author":"Landecker","year":"2019","journal-title":"Palgrave Commun."},{"key":"10.1016\/j.jmb.2026.169892_b0060","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1126\/science.7001623","article-title":"Tetracycline-labeled human bone from ancient Sudanese Nubia (A.D. 350)","volume":"209","author":"Bassett","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.jmb.2026.169892_b0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3389\/fmicb.2010.00134","article-title":"A brief history of the antibiotic era: lessons learned and challenges for the future","volume":"1","author":"Aminov","year":"2010","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jmb.2026.169892_b0070","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2011.06354.x","article-title":"The history of the tetracyclines","volume":"1241","author":"Nelson","year":"2011","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jmb.2026.169892_b0075","doi-asserted-by":"crossref","first-page":"8840","DOI":"10.1002\/anie.201310843","article-title":"The evolving role of chemical synthesis in antibacterial drug discovery","volume":"53","author":"Wright","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jmb.2026.169892_b0080","doi-asserted-by":"crossref","first-page":"6057","DOI":"10.3390\/molecules26196057","article-title":"Drugs that changed society: history and current status of the early antibiotics: salvarsan, sulfonamides, and beta-lactams","volume":"26","author":"Christensen","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.jmb.2026.169892_b0085","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/anie.200461471","article-title":"The composition of Ehrlich's salvarsan: resolution of a century-old debate","volume":"44","author":"Lloyd","year":"2005","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jmb.2026.169892_b0090","doi-asserted-by":"crossref","DOI":"10.1021\/cen-v083n025.p116","article-title":"Salvarsan","author":"Yarnell","year":"2005","journal-title":"Chem. Eng. News"},{"key":"10.1016\/j.jmb.2026.169892_b0095","series-title":"The Discovery and Development of Penicillin 1928\u20131945","author":"Aldridge","year":"1999"},{"key":"10.1016\/j.jmb.2026.169892_b0100","series-title":"Prontosil","author":"Stork","year":"2005"},{"key":"10.1016\/j.jmb.2026.169892_b0105","doi-asserted-by":"crossref","DOI":"10.1128\/ecosalplus.ESP-0010-2020","article-title":"Peptidoglycan: structure, synthesis, and regulation","volume":"9","author":"Garde","year":"2021","journal-title":"EcoSal Plus"},{"key":"10.1016\/j.jmb.2026.169892_b0110","doi-asserted-by":"crossref","first-page":"8884","DOI":"10.1021\/acs.chemrev.1c00773","article-title":"The bacterial cell wall: from lipid II flipping to polymerization","volume":"122","author":"Kumar","year":"2022","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jmb.2026.169892_b0115","doi-asserted-by":"crossref","first-page":"a030239","DOI":"10.1101\/cshperspect.a030239","article-title":"Appropriate targets for antibacterial drugs","volume":"6","author":"Silver","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jmb.2026.169892_b0120","doi-asserted-by":"crossref","first-page":"a025247","DOI":"10.1101\/cshperspect.a025247","article-title":"Beta-lactams and beta-lactamase inhibitors: an overview","volume":"6","author":"Bush","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jmb.2026.169892_b0125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/ijms22020617","article-title":"The odd couple(s): an overview of beta-lactam antibiotics bearing more than one pharmacophoric group","volume":"22","author":"De Rosa","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmb.2026.169892_b0130","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"De Oliveira","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jmb.2026.169892_b0135","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.VMBF-0016-2015","article-title":"Mechanisms of antibiotic resistance","volume":"4","author":"Munita","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.jmb.2026.169892_b0140","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3389\/fmicb.2018.02153","article-title":"The role of outer membrane proteins and lipopolysaccharides for the sensitivity of Escherichia coli to antimicrobial peptides","volume":"9","author":"Ebbensgaard","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jmb.2026.169892_b0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1124\/pr.55.1.2","article-title":"Mechanisms of antimicrobial peptide action and resistance","volume":"55","author":"Yeaman","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jmb.2026.169892_b0150","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1128\/CMR.00064-16","article-title":"Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes","volume":"30","author":"Poirel","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.jmb.2026.169892_b0155","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0160","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrm2352","article-title":"A structural understanding of the dynamic ribosome machine","volume":"9","author":"Steitz","year":"2008","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"10.1016\/j.jmb.2026.169892_b0165","doi-asserted-by":"crossref","first-page":"a025361","DOI":"10.1101\/cshperspect.a025361","article-title":"Bacterial protein synthesis as a target for antibiotic inhibition","volume":"6","author":"Arenz","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jmb.2026.169892_b0170","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-biochem-062917-011942","article-title":"Ribosome-targeting antibiotics: modes of action, mechanisms of resistance, and implications for drug design","volume":"87","author":"Lin","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jmb.2026.169892_b0175","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drup.2010.08.003","article-title":"Aminoglycoside modifying enzymes","volume":"13","author":"Ramirez","year":"2010","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.jmb.2026.169892_b0180","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bcp.2005.10.052","article-title":"Dihydrofolate reductase inhibitors as antibacterial agents","volume":"71","author":"Hawser","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jmb.2026.169892_b0185","doi-asserted-by":"crossref","first-page":"935","DOI":"10.4155\/fmc-2017-0168","article-title":"Folate biosynthesis pathway: mechanisms and insights into drug design for infecitous diseases","volume":"10","author":"Bertacine Dias","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0190","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028324","article-title":"Antibacterial antifolates: from development through resistance to the next generation","volume":"6","author":"Estrada","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.jmb.2026.169892_b0195","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/1381612013398013","article-title":"Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde","volume":"7","author":"Anderson","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.jmb.2026.169892_b0200","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2026.169892_b0205","doi-asserted-by":"crossref","first-page":"12300","DOI":"10.1074\/jbc.M113.529164","article-title":"Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding","volume":"289","author":"Mustaev","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0210","series-title":"Antimicrobial Resistance in the 21st Century","first-page":"507","article-title":"Fluoroquinolone interactions with bacterial type II topoisomerases and target-mediated drug resistance","author":"Gibson","year":"2018"},{"key":"10.1016\/j.jmb.2026.169892_b0215","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1039\/C9MD00120D","article-title":"Quinolone antibiotics","volume":"10","author":"Pham","year":"2019","journal-title":"Med. Chem. Commun."},{"key":"10.1016\/j.jmb.2026.169892_b0220","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1021\/acsinfecdis.4c00128","article-title":"Gyrase and topoisomerase IV: recycling old targets for new antibacterials to combat fluoroquinolone resistance","volume":"10","author":"Collins","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0225","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/ijms27010496","article-title":"Gyrase and topoisomerase IV as antibacterial targets for gepotidacin and zoliflodacin: teaching old enzymes new tricks","volume":"27","author":"Osheroff","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmb.2026.169892_b0230","series-title":"Knots, Low-Dimensional Topology and Applications","first-page":"411","article-title":"Regulation of DNA by topoisomerases: mathematics at the molecular level","author":"Ashley","year":"2019"},{"key":"10.1016\/j.jmb.2026.169892_b0235","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3201\/eid0702.010239","article-title":"Emerging mechanisms of fluoroquinolone resistance","volume":"7","author":"Hooper","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0240","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.jmb.2026.169892_b0245","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.3390\/molecules25235662","article-title":"Quinolones: mechanism, lethality and their contributions to antibiotic resistance","volume":"25","author":"Bush","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.jmb.2026.169892_b0250","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1016\/j.jmb.2019.07.008","article-title":"DNA topoisomerase inhibitors: trapping a DNA-cleaving machine in motion","volume":"431","author":"Bax","year":"2019","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.169892_b0255","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1073\/pnas.77.4.1847","article-title":"DNA gyrase action involves the introduction of transient double-strand breaks into DNA","volume":"77","author":"Mizuuchi","year":"1980","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169892_b0260","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0092-8674(92)90356-H","article-title":"The role of topoisomerase IV in partitioning bacterial replicons and the structure of catenated intermediates in DNA replication","volume":"71","author":"Adams","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2026.169892_b0265","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1101\/gad.9.22.2859","article-title":"Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli","volume":"9","author":"Zechiedrich","year":"1995","journal-title":"Genes Dev."},{"key":"10.1016\/j.jmb.2026.169892_b0270","doi-asserted-by":"crossref","first-page":"8103","DOI":"10.1074\/jbc.275.11.8103","article-title":"Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli","volume":"275","author":"Zechiedrich","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0275","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-biochem-061809-100002","article-title":"New mechanistic and functional insights into DNA topoisomerases","volume":"82","author":"Chen","year":"2013","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.jmb.2026.169892_b0280","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1093\/nar\/gkz1230","article-title":"Modulated control of DNA supercoiling balance by the DNA-wrapping domain of bacterial gyrase","volume":"48","author":"Hobson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.169892_b0285","doi-asserted-by":"crossref","first-page":"6027","DOI":"10.1093\/nar\/gkab270","article-title":"What makes a type IIA topoisomerase a gyrase or a topo IV?","volume":"49","author":"Hirsch","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.169892_b0290","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1038\/s41467-019-12914-y","article-title":"Cryo-EM structure of the complete E. coli DNA gyrase nucleoprotein complex","volume":"10","author":"Vanden Broeck","year":"2019","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.169892_b0295","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1038\/s41467-018-05406-y","article-title":"Structural insights into the gating of DNA passage by the topoisomerase II DNA-gate","volume":"9","author":"Chen","year":"2018","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.169892_b0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jmb.2012.07.014","article-title":"The structure of DNA-bound human topoisomerase II\u03b1: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage","volume":"424","author":"Wendorff","year":"2012","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.169892_b0305","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/deacc2fd-665b-4736-b668-dc69a38bb4f9","article-title":"Structural basis of gate-DNA breakage and resealing by type II topoisomerases","volume":"5","author":"Laponogov","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jmb.2026.169892_b0310","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nature06396","article-title":"Structural basis for gate-DNA recognition and bending by type IIA topoisomerases","volume":"450","author":"Dong","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2026.169892_b0315","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/nar\/gkn937","article-title":"The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing","volume":"37","author":"Deweese","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.169892_b0320","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0092-8674(92)90558-T","article-title":"The capture of a DNA double helix by an ATP-dependent protein clamp: a key step in DNA transport by type II DNA topoisomerases","volume":"71","author":"Roca","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2026.169892_b0325","doi-asserted-by":"crossref","first-page":"8096","DOI":"10.1016\/S0021-9258(18)53067-2","article-title":"On the coupling between ATP usage and DNA transport by yeast DNA topoisomerase II","volume":"268","author":"Lindsley","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0330","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/0092-8674(94)90222-4","article-title":"DNA transport by a type II DNA topoisomerase: evidence in favor of a two-gate mechanism","volume":"77","author":"Roca","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2026.169892_b0335","doi-asserted-by":"crossref","first-page":"5960","DOI":"10.1073\/pnas.75.12.5960","article-title":"DNA gyrase: subunit structure and ATPase activity of the purified enzyme","volume":"75","author":"Mizuuchi","year":"1978","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169892_b0340","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/0092-8674(90)90172-B","article-title":"New topoisomerase essential for chromosome segregation in E. coli","volume":"63","author":"Kato","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.jmb.2026.169892_b0345","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2958.1994.tb00458.x","article-title":"Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones","volume":"13","author":"Ferrero","year":"1994","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.jmb.2026.169892_b0350","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.biochi.2006.12.009","article-title":"Origin and evolution of DNA topoisomerases","volume":"89","author":"Forterre","year":"2007","journal-title":"Biochimie"},{"key":"10.1016\/j.jmb.2026.169892_b0355","doi-asserted-by":"crossref","DOI":"10.1128\/ecosalplus.esp-0010-2014","article-title":"DNA topoisomerases","volume":"6","author":"Bush","year":"2015","journal-title":"EcoSal Plus"},{"key":"10.1016\/j.jmb.2026.169892_b0360","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12551-016-0237-3","article-title":"The regulatory role of DNA supercoiling in nucleoprotein complex assembly and genetic activity","volume":"8","author":"Muskhelishvili","year":"2016","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.jmb.2026.169892_b0365","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0924-8579(00)00192-8","article-title":"The fluoroquinolone antibacterials: past, present and future perspectives","volume":"16","author":"Appelbaum","year":"2000","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"Suppl 1","key":"10.1016\/j.jmb.2026.169892_b0370","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jac\/dkg208","article-title":"The quinolones: decades of development and use","volume":"51","author":"Emmerson","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0375","doi-asserted-by":"crossref","first-page":"11801","DOI":"10.1073\/pnas.92.25.11801","article-title":"Topoisomerase IV is a target of quinolones in Escherichia coli","volume":"92","author":"Khodursky","year":"1995","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169892_b0380","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/nyas.12830","article-title":"Mechanisms of drug resistance: quinolone resistance","volume":"1354","author":"Hooper","year":"2015","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.jmb.2026.169892_b0385","series-title":"DNA Topoisomerases","first-page":"47","article-title":"DNA topoisomerases as targets for antibacterial agents","author":"Hiasa","year":"2018"},{"key":"10.1016\/j.jmb.2026.169892_b0390","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1073\/pnas.73.11.3872","article-title":"DNA gyrase: an enzyme that introduces superhelical turns into DNA","volume":"73","author":"Gellert","year":"1976","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169892_b0395","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1073\/pnas.74.11.4767","article-title":"Mechanism of action of nalidixic acid: purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme","volume":"74","author":"Sugino","year":"1977","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169892_b0400","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1021\/jm501881c","article-title":"Origins of the quinolone class of antibacterials: an expanded \u201cdiscovery story\u201d","volume":"58","author":"Bisacchi","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0405","doi-asserted-by":"crossref","first-page":"24481","DOI":"10.1016\/S0021-9258(20)80551-1","article-title":"Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions","volume":"268","author":"Peng","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0410","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/nsmb.1892","article-title":"Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance","volume":"17","author":"Wohlkonig","year":"2010","journal-title":"Nature Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.169892_b0415","first-page":"165","article-title":"Four ways to skin a cat: inhibition of bacterial topoisomerases leading to the clinic","volume":"vol. I","author":"Basarab","year":"2018"},{"key":"10.1016\/j.jmb.2026.169892_b0420","doi-asserted-by":"crossref","first-page":"35927","DOI":"10.1074\/jbc.274.50.35927","article-title":"Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV: changes in drug mechanism across evolutionary boundaries","volume":"274","author":"Anderson","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0425","doi-asserted-by":"crossref","first-page":"17879","DOI":"10.1074\/jbc.273.28.17879","article-title":"Topoisomerase IV catalysis and the mechanism of quinolone action","volume":"273","author":"Anderson","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0430","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2958.2007.05642.x","article-title":"Antibiotic-mediated recombination: ciprofloxacin stimulates SOS-independent recombination of divergent sequences in Escherichia coli","volume":"64","author":"Lopez","year":"2007","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.jmb.2026.169892_b0435","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jac\/dks456","article-title":"Opposing effects of aminocoumarins and fluoroquinolones on the SOS response and adaptability in Staphylococcus aureus","volume":"68","author":"Schroder","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0440","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.37.4.696","article-title":"Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli","volume":"37","author":"Heisig","year":"1993","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0445","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ejmech.2013.01.057","article-title":"Antibacterial action of quinolones: from target to network","volume":"66","author":"Cheng","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0450","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/infdis\/165.4.667","article-title":"High-level quinolone resistance in clinical isolates of Campylobacter jejuni","volume":"165","author":"Segreti","year":"1992","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0455","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1128\/AAC.43.1.62","article-title":"Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa","volume":"43","author":"Mouneimne","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0460","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1128\/AAC.49.6.2479-2486.2005","article-title":"Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates","volume":"49","author":"Korzheva","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0465","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.00665-08","article-title":"Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates","volume":"53","author":"Morgan-Linnell","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0470","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1071\/SH18225","article-title":"Genotypic determinants of fluoroquinolone and macrolide resistance in Neisseria gonorrhoeae","volume":"16","author":"Hall","year":"2019","journal-title":"Sex. Health"},{"key":"10.1016\/j.jmb.2026.169892_b0475","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijantimicag.2018.12.004","article-title":"Analysis of mutational patterns in quinolone resistance-determining regions of gyrA and parC of clinical isolates","volume":"53","author":"Ostrer","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jmb.2026.169892_b0480","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/nsmb.1604","article-title":"Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases","volume":"16","author":"Laponogov","year":"2009","journal-title":"Nature Struct. Mol. Biol."},{"key":"10.1016\/j.jmb.2026.169892_b0485","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2026.169892_b0490","doi-asserted-by":"crossref","first-page":"9671","DOI":"10.1073\/pnas.89.20.9671","article-title":"Quinolone binding to DNA is mediated by magnesium ions","volume":"89","author":"Palu","year":"1992","journal-title":"PNAS"},{"key":"10.1016\/j.jmb.2026.169892_b0495","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0010-8545(02)00027-9","article-title":"The interactions of metal ions with quinolone antibacterial agents","volume":"232","author":"Turel","year":"2002","journal-title":"Coordin. Chem. Rev."},{"key":"10.1016\/j.jmb.2026.169892_b0500","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.1021\/bi500682e","article-title":"Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV","volume":"53","author":"Aldred","year":"2014","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2026.169892_b0505","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/bi2013905","article-title":"Drug interactions with bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance","volume":"51","author":"Aldred","year":"2012","journal-title":"Biochemistry"},{"key":"10.1016\/j.jmb.2026.169892_b0510","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1093\/nar\/gkt124","article-title":"Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance","volume":"41","author":"Aldred","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jmb.2026.169892_b0515","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/976273","article-title":"Global fluoroquinolone resistance epidemiology and implictions for clinical use","volume":"2012","author":"Dalhoff","year":"2012","journal-title":"Interdiscip. Perspect. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0520","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3947\/ic.2014.46.4.226","article-title":"Clinical importance and epidemiology of quinolone resistance","volume":"46","author":"Kim","year":"2014","journal-title":"Infect. Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0525","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1128\/AAC.40.10.2321","article-title":"Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae","volume":"40","author":"Pan","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0530","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1128\/AAC.44.8.2160-2165.2000","article-title":"Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis","volume":"44","author":"Fournier","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0535","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2958.1994.tb01297.x","article-title":"Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates","volume":"14","author":"Belland","year":"1994","journal-title":"Mol. Microbiol."},{"key":"10.1016\/j.jmb.2026.169892_b0540","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijantimicag.2010.11.022","article-title":"Contribution of mutations in DNA gyrase and topoisomerase IV genes to ciprofloxacin resistance in Escherichia coli clinical isolates","volume":"37","author":"Bansal","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jmb.2026.169892_b0545","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1021\/acs.jmedchem.9b01738","article-title":"Two decades of successful SAR-grounded stories of the novel bacterial topoisomerase inhibitors (NBTIs)","volume":"63","author":"Kolaric","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0550","article-title":"Fluoroquinolones: neurological complications and side effects in clinical practice","volume":"16","author":"Anwar","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jmb.2026.169892_b0555","unstructured":"Coates, W.J., Gwynn, M. N., Hatton, I. K., Masters, P. J., Pearson, N. D., Rahman, S. S., Slocombe, B., Warrack, J. D. Quinoline derivatives as antibacterials. C07D 401\/06, A61K 31\/34, C07D 401\/12, 401\/14, 405\/14, ed1999."},{"key":"10.1016\/j.jmb.2026.169892_b0560","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1016\/j.bmcl.2007.03.003","article-title":"Novel pyrazole derivatives as potent inhibitors of type II topoisomerases. Part 1: synthesis and preliminary SAR analysis","volume":"17","author":"Gomez","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0565","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.bmcl.2007.03.004","article-title":"Tetrahydroindazole inhibitors of bacterial type II topoisomerases. Part 2: SAR development and potency against multidrug-resistant strains","volume":"17","author":"Wiener","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0570","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0575","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1021\/acs.jmedchem.6b01831","article-title":"Synthesis and characterization of tetrahydropyran-based bacterial topoisomerase inhibitors with antibacterial activity against gram-negative bacteria","volume":"60","author":"Surivet","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0580","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1021\/acs.jmedchem.2c00039","article-title":"The structural features of novel bacterial topoisomerase inhibitors that define their activity on topoisomerase IV","volume":"65","author":"Kokot","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0585","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1128\/AAC.00496-08","article-title":"Mechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases","volume":"52","author":"Black","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0590","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1021\/acsmedchemlett.0c00428","article-title":"Dioxane-linked amide derivatives as novel bacterial topoisomerase inhibitors against gram-positive Staphylococcus aureus","volume":"11","author":"Lu","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0595","doi-asserted-by":"crossref","first-page":"15214","DOI":"10.1021\/acs.jmedchem.1c01250","article-title":"Optimization of topoIV potency, ADMET Properties, and hERG Inhibition of 5-amino-1,3-dioxane-linked novel bacterial topoisomerase inhibitors: identification of a lead with in vivo efficacy against MRSA","volume":"64","author":"Lu","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0600","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00482-23","article-title":"Novel bacterial topoisomerase inhibitors: unique targeting activities of amide enzyme-binding motifs for tricyclic analogs","volume":"67","author":"Mann","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0605","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512107","article-title":"Actions of a novel bacterial topoisomerase inhibitor against Neisseria gonorrhoeae gyrase and topoisomerase IV: enhancement of double-stranded DNA breaks","volume":"24","author":"Dauda","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jmb.2026.169892_b0610","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","article-title":"Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: genetic and biochemical evidence for well-balanced dual-targeting","volume":"10","author":"Oviatt","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0615","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1021\/acsinfecdis.5c00497","article-title":"Mechanism of action of gepotidacin: well-balanced dual-targeting against Neisseria gonorrhoeae gyrase and topoisomerase IV in cells and in vitro","author":"Oviatt","year":"2025","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0620","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/acsinfecdis.5c00860","article-title":"Activities of the novel bacterial topoisomerase Inhibitor OSUAB-0284 against the biothreat pathogen Bacillus anthracis and its type II topoisomerases","volume":"12","author":"Mann","year":"2026","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0625","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1021\/acsmedchemlett.4c00162","article-title":"Development of novel bacterial topoisomerase inhibitors assisted by computational screening","volume":"15","author":"Powell","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0630","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s42003-025-09055-y","article-title":"Structural interactions of BWC0977 with Klebsiella pneumoniae topoisomerase IV and biochemical basis of its broad-spectrum activity","volume":"8","author":"Nandishaiah","year":"2025","journal-title":"Commun. Biol."},{"key":"10.1016\/j.jmb.2026.169892_b0635","first-page":"804","article-title":"New inhibitors of bacterial topoisomerase GyrA\/ParC subunits","volume":"10","author":"Black","year":"2009","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.jmb.2026.169892_b0640","unstructured":"A. Tarral, M. Rangaraju, H. Merdjan, A.M. Girard, C. Delachaume, J. Lowther, Plasma bactericidal activity of NXL101 in healthy volunteers after single intravenous administrations of 50\u00a0mg to 700\u00a0mg, in: Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., A-8082007, p. 25."},{"key":"10.1016\/j.jmb.2026.169892_b0645","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.4155\/fmc-2018-0272","article-title":"Novel bacterial topoisomerase inhibitors: challenges and perspectives in reducing hERG toxicity","volume":"10","author":"Kolari\u010d","year":"2018","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0650","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/jm300690s","article-title":"Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pKa: antibacterial agents with an improved safety profile","volume":"55","author":"Reck","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0655","doi-asserted-by":"crossref","first-page":"7396","DOI":"10.1021\/jm400963y","article-title":"Design, synthesis, and characterization of novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram-positive activity","volume":"56","author":"Surivet","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0660","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1021\/jm2008826","article-title":"Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity","volume":"54","author":"Reck","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0665","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/j.bmcl.2018.06.003","article-title":"Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety","volume":"28","author":"Li","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0670","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1021\/acsinfecdis.8b00375","article-title":"1,3-Dioxane-linked bacterial topoisomerase inhibitors with enhanced antibacterial activity and reduced hERG inhibition","volume":"5","author":"Li","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106087","article-title":"Diminishing hERG inhibitory activity of aminopiperidine-naphthyridine linked NBTI antibacterials by structural and physicochemical optimizations","volume":"128","author":"Kokot","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115160","article-title":"Amide containing NBTI antibacterials with reduced hERG inhibition, retained antimicrobial activity against gram-positive bacteria and in vivo efficacy","volume":"250","author":"Kokot","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0685","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/jm501590q","article-title":"Novel tetrahydropyran-based bacterial topoisomerase inhibitors with potent anti-gram positive activity and improved safety profile","volume":"58","author":"Surivet","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0690","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/acsmedchemlett.2c00111","article-title":"1,3-Dioxane-linked novel bacterial topoisomerase inhibitors: expanding structural diversity and the antibacterial spectrum","volume":"13","author":"Lu","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0695","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1016\/j.bmcl.2013.03.047","article-title":"Novel quinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV","volume":"23","author":"Mitton-Fry","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0700","doi-asserted-by":"crossref","first-page":"7483","DOI":"10.1016\/j.bmcl.2011.09.114","article-title":"Novel cyclohexyl-amides as potent antibacterials targeting bacterial type IIA topoisomerases","volume":"21","author":"Miles","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0705","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1016\/j.bmcl.2015.04.002","article-title":"Structure activity relationship of substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-4)","volume":"25","author":"Singh","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0710","doi-asserted-by":"crossref","first-page":"3630","DOI":"10.1016\/j.bmcl.2015.06.061","article-title":"Structure activity relationship of C-2 ether substituted 1,5-naphthyridine analogs of oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-5)","volume":"25","author":"Singh","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0715","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1016\/j.bmcl.2013.07.013","article-title":"Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases","volume":"23","author":"Miles","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0720","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/ml500069w","article-title":"Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad spectrum antibacterial agents","volume":"5","author":"Singh","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0725","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.bmcl.2015.03.044","article-title":"Tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of left-hand-side moiety (Part-2)","volume":"25","author":"Singh","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0730","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/j.bmcl.2016.03.106","article-title":"Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases","volume":"26","author":"Miles","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0735","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0740","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02100-16","article-title":"Novel bacterial topoisomerase inhibitors with potent broad-spectrum activity against drug-resistant bacteria","volume":"61","author":"Charrier","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112324","article-title":"Novel bacterial topoisomerase inhibitors derived from isomannide","volume":"199","author":"Okumu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0750","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nature22308","article-title":"Predictive compound accumulation rules yield a broad-spectrum antibiotic","volume":"545","author":"Richter","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jmb.2026.169892_b0755","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1021\/acsmedchemlett.1c00345","article-title":"Structurally optimized potent dual-targeting NBTI antibacterials with an enhanced bifurcated halogen-bonding propensity","volume":"12","author":"Kokot","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0760","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1021\/acsmedchemlett.5c00060","article-title":"Structural and mechanistic insights into atypical bacterial topoisomerase inhibitors","volume":"16","author":"Toth","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jmb.2026.169892_b0765","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1021\/cr4003984","article-title":"Non-quinolone inhibitors of bacterial type IIA topoisomerases: a feat of bioisosterism","volume":"114","author":"Mayer","year":"2014","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jmb.2026.169892_b0770","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1016\/j.bmc.2014.07.040","article-title":"Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa","volume":"22","author":"Reck","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jmb.2026.169892_b0775","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1021\/acs.oprd.5c00033","article-title":"Decagram-scale synthesis of the novel bacterial topoisomerase inhibitor OSUAB-0284","volume":"29","author":"West","year":"2025","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jmb.2026.169892_b0780","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jmb.2026.169892_b0785","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","article-title":"Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study","volume":"405","author":"Ross","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jmb.2026.169892_b0790","series-title":"Blujepa (Gepotidacin) Approved by the US FDA for Treatment of Uncomplicated Urinary Tract Infections (uUTIs) in Female Adults and Paediatric Patients 12 Years of Age and Older","author":"GlaxoSmithKline","year":"2025"},{"key":"10.1016\/j.jmb.2026.169892_b0795","series-title":"Blujepa (Gepotidacin) Approved by US FDA as Oral Option for Treatment of Uncomplicated Urogenital Gonorrhoea (uGC)","author":"GlaxoSmithKline","year":"2025"},{"key":"10.1016\/j.jmb.2026.169892_b0800","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3109\/00498254.2015.1112933","article-title":"The metabolism and disposition of GSK2140944 in healthy human subjects","volume":"46","author":"Negash","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jmb.2026.169892_b0805","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/cpdd.807","article-title":"Pharmacokinetics of gepotidacin in renal impairment","volume":"9","author":"Hossain","year":"2020","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jmb.2026.169892_b0810","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/cpdd.913","article-title":"Pharmacokinetics of gepotidacin in subjects with normal hepatic function and hepatic impairment","volume":"10","author":"Hossain","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.jmb.2026.169892_b0815","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01263-21","article-title":"Pharmacokinetics of oral formulations of gepotidacin (GSK2140944), a triazaacenaphthylene bacterial type II topoisomerase inhibitor, in healthy adult and adolescent participants","volume":"66","author":"Barth","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0820","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1111\/cts.13359","article-title":"Pharmacokinetics, safety, and tolerability of gepotidacin administered as single or repeat ascending doses, in healthy adults and elderly subjects","volume":"15","author":"Tiffany","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jmb.2026.169892_b0825","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1128\/AAC.00625-15","article-title":"Pharmacodynamic profile of GSK2140944 against methicillin-resistant Staphylococcus aureus in a murine lung infection model","volume":"59","author":"So","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0830","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01497-23","article-title":"Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax","volume":"68","author":"Hilliard","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0835","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02047-16","article-title":"In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae","volume":"61","author":"Farrell","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0840","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5582\/ddt.2025.01028","article-title":"Gepotidacin: the first-in-class triazaacenaphthylene antibiotic approved for the treatment of uncomplicated urinary tract infections","volume":"19","author":"Hu","year":"2025","journal-title":"Drug. Discov. Ther."},{"key":"10.1016\/j.jmb.2026.169892_b0845","first-page":"322","article-title":"New antibiotic for urinary tract infections nabs FDA approval","volume":"24","author":"Mullard","year":"2025","journal-title":"Nature Rev. Drug Discov."},{"key":"10.1016\/j.jmb.2026.169892_b0850","doi-asserted-by":"crossref","first-page":"r1825","DOI":"10.1136\/bmj.r1825","article-title":"UTIs: New antibiotic for women and girls is approved in UK","volume":"390","author":"Labcobucci","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.jmb.2026.169892_b0855","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/cid\/ciab560","article-title":"Antimicrobial resistance trends in urine Escherichia coli isolates from adult and adolescent females in the United States from 2011 to 2019: rising ESBL strains and impact on patient management","volume":"73","author":"Kaye","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0860","first-page":"40","article-title":"Urinary tract infection in women","volume":"20","author":"Czajkowski","year":"2021","journal-title":"Prz. Menopauzalny"},{"key":"10.1016\/j.jmb.2026.169892_b0865","article-title":"Disease burden and long-term trends of urinary tract infections: a worldwide report","volume":"10","author":"Yang","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.jmb.2026.169892_b0870","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofw281","article-title":"The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998\u20132011","volume":"4","author":"Simmering","year":"2017","journal-title":"Open Forum. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0875","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina","year":"2019","journal-title":"Ther. Adv. Urol."},{"key":"10.1016\/j.jmb.2026.169892_b0880","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1007\/s00345-019-03071-4","article-title":"Epidemiology of urological infections: a global burden","volume":"38","author":"Ozturk","year":"2020","journal-title":"World J. Urol."},{"key":"10.1016\/j.jmb.2026.169892_b0885","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1017\/ash.2025.10045","article-title":"Assessing the burden of outpatient urinary tract infections in the United States: analysis of nationwide ambulatory data (2016\u20132019)","volume":"5","author":"Advani","year":"2025","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"10.1016\/j.jmb.2026.169892_b0890","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.14475","article-title":"Management of urinary tract infections and antibiotic susceptibility patterns of bacterial isolates","volume":"75","author":"Amawi","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jmb.2026.169892_b0895","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrmicro.2017.169","article-title":"Neisseria gonorrhoeae host adaptation and pathogenesis","volume":"16","author":"Quillin","year":"2018","journal-title":"Nature Rev. Microbiol."},{"key":"10.1016\/j.jmb.2026.169892_b0900","series-title":"Gonorrhoea (Neissseria gonorrhoeae Infection)","author":"World Health Organization","year":"2023"},{"key":"10.1016\/j.jmb.2026.169892_b0905","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41572-019-0128-6","article-title":"Gonorrhoea","volume":"5","author":"Unemo","year":"2019","journal-title":"Nature Rev. Dis. Primers."},{"issue":"Suppl 1","key":"10.1016\/j.jmb.2026.169892_b0910","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/clinids\/20.Supplement_1.S47","article-title":"Drugs of choice for the treatment of uncomplicated gonococcal infections","volume":"20","author":"Moran","year":"1995","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0915","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/14656566.5.4.829","article-title":"The use of fluoroquinolones in gonorrhoea: the increasing problem of resistance","volume":"5","author":"Dan","year":"2004","journal-title":"Expert Opin. Pharmacol."},{"key":"10.1016\/j.jmb.2026.169892_b0920","first-page":"332","article-title":"Update to CDC\u2019s sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections","volume":"56","author":"Centers for Disease Control and Prevention","year":"2007","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.jmb.2026.169892_b0925","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017-18: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.jmb.2026.169892_b0930","doi-asserted-by":"crossref","first-page":"e00207","DOI":"10.1128\/AAC.00207-19","article-title":"Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations","volume":"63","author":"Szili","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0935","doi-asserted-by":"crossref","first-page":"e01221","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0940","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1021\/acsinfecdis.5c01108","article-title":"Targeting of the Gram-negative outer membrane for antibiotic discovery and potentiation","volume":"12","author":"Draveny","year":"2026","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0945","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1038\/s41467-024-52557-2","article-title":"BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections","volume":"15","author":"Hameed","year":"2024","journal-title":"Nature Commun."},{"key":"10.1016\/j.jmb.2026.169892_b0950","series-title":"Indentification and Optimization of Broad Spectrum Novel Bacterial Topoisomerase Inhibitors (NBTIs): Anti-microbial Potency and Mechanism of Action (BWC0977)","author":"Hameed","year":"2018"},{"key":"10.1016\/j.jmb.2026.169892_b0955","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1128\/AAC.43.5.1129","article-title":"Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones","volume":"43","author":"Pan","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jmb.2026.169892_b0960","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acsinfecdis.4c00041","article-title":"Target-mediated fluoroquinolone resistance in Neisseria gonorrhoeae: actions of ciprofloxacin against gyrase and topoisomerase IV","volume":"10","author":"Collins","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.jmb.2026.169892_b0965","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jmb.2026.169892_b0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44386-024-00001-2","article-title":"Structure and dynamics in drug discovery","volume":"1","author":"Wei","year":"2024","journal-title":"Npj Drug Discov."},{"key":"10.1016\/j.jmb.2026.169892_b0975","doi-asserted-by":"crossref","first-page":"18278","DOI":"10.1021\/acsomega.4c00036","article-title":"Dynamic profiling and binding affinity prediction of NBTI antibacterials against DNA gyrase enzyme by multidimensional machine learning and molecular dynamics simulations","volume":"9","author":"Kokot","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.jmb.2026.169892_b0980","article-title":"The future of pharmaceuticals: artificial intelligence in drug discovery and development","volume":"15","author":"Fu","year":"2025","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jmb.2026.169892_b0985","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4792","article-title":"UCSF ChimeraX:Tools for structure building and analysis","volume":"32","author":"Meng","year":"2023","journal-title":"Protein Sci."}],"container-title":["Journal of Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283626002652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022283626002652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:57:58Z","timestamp":1786035478000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022283626002652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":197,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0022283626002652"],"URL":"https:\/\/doi.org\/10.1016\/j.jmb.2026.169892","relation":{},"ISSN":["0022-2836"],"issn-type":[{"value":"0022-2836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Bacterial Topoisomerase Inhibitors: A New Front in an Old War","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmb.2026.169892","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"169892"}}